ArticleCancer immunology, immunotherapy : CII2020

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.

Anne Fröhlich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.